NEW YORK (GenomeWeb News) – PerkinElmer today said that its planned acquisition of Caliper Life Sciences has cleared anti-trust reviews in the US and Germany.
The $600 million deal, which was signed early last month, still requires the approval of Caliper's stockholders, among other remaining conditions. The firms previously said that they expect the transaction to close in the fourth quarter of this year, but they didn't provide an update to that expectation today.
The deal will broaden PerkinElmer's reach in the life sciences research space, providing the firm with Caliper's portfolio of imaging, microfluidics, automation, and sample preparation platforms and technologies. It also will combine Caliper's imaging instrumentation for in vivo imaging applications with PerkinElmer's broad offering of imaging reagents and set up the combined firm with further growth opportunities in molecular diagnostics.